Linear growth of very young asthmatic children treated with high-dose nebulized budesonide.
The aim of this open study was to observe linear growth in young children with asthma treated with nebulized budesonide. Infants and young children (< 3 years old) with severe uncontrolled asthma were studied. They were treated with nebulized budesonide (1-4 mg day-1) and treated for at least 6 months. Height standard deviation scores (HtSDS) were measured before ("pre-measurements") immediately prior to commencing nebulized budesonide therapy (baseline) and after at least 6 months of therapy ("post-measurements"). The mean HtSDS score at pretreatment was -0.21 and at baseline had fallen further to -0.46. The mean HtSDS increased to -0.17 when the post-measurements were made (p = 0.035) after at least 6 months of nebulized budesonide therapy. Treatment with nebulized budesonide for longer than 6 months in very young children with severe asthma was not associated with reduced linear growth.
Reid
A
A
Royal Belfast Hospital for Sick Children, UK.
Murphy
C
C
Steen
H J
HJ
McGovern
V
V
Shields
M D
MD
D000280:Administration, Inhalation; D000367:Age Factors; D001249:Asthma / Q000188:drug therapy*; D001827:Body Height / Q000187:drug effects*; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000009:adverse effects*; D019819:Budesonide; D002675:Child, Preschool; D006130:Growth Disorders / Q000139:chemically induced*; D006801:Humans; D007223:Infant; D009330:Nebulizers and Vaporizers; D011282:Pregnenediones / Q000008:administration & dosage / Q000009:adverse effects*; D011446:Prospective Studies; D013997:Time Factors
D001993:Bronchodilator Agents; D011282:Pregnenediones; D019819:Budesonide